Latest ResMed News & Updates

See the latest news and media coverage for ResMed. We track all announcements, press releases, and industry mentions in real time, all in one place.

ResMed

Medical technology company for sleep and respiratory care

resmed.com

Headquarters: San Diego, United States
Company type: Public company
Number of employees: 9,000–10,000
Industry: Medical Equipment, Supplies & Distribution

Last updated October 9

Latest news about ResMed

In short: ResMed reported $5.7B FY2026 revenue, acquired Noctrix, divested MatrixCare, and issued an Astral ventilator safety correction.

Company announcements

August 17 ResMed

ResMed appoints Carol Burt as lead director

Carol Burt succeeds retiring board member Ron Taylor after his 21-year tenure, effective November 15, 2026.

August 14 ResMed

ResMed CEO awarded Singapore's Public Service Star

The award recognizes ResMed's contributions over 20 years in Singapore, including advanced manufacturing and R&D expansion.

July 7 ResMed

ResMed announces agreement to sell MatrixCare business

Sharpens focus on high-growth sleep and connected care markets.

June 1 ResMed

ResMed completes acquisition of Noctrix Health

The deal adds Nidra TOMAC therapy for Restless Legs Syndrome.

Media coverage

October 9 Kalkine Media

ResMed (ASX:RMD) Leans on Buybacks and Higher Dividend

ResMed unveiled a large share repurchase and a higher dividend after a business sale. See the earnings test due later this month.

September 30 Kalkine Media

Can ResMed (ASX:RMD) Hit Its Outlook After Retiring the Astral Ventilator?

ResMed reaffirms its full-year outlook despite an Astral ventilator safety action, as its shares ease in New York trade.

September 15 Yahoo Finance

This Analyst Just Upgraded ResMed Stock. Here's Why.

ResMed stock rallies on a bullish RBC Capital research note. Here's why analyst Craig Wong-Pan raised his price target on RMD shares today.

September 15 Yahoo Finance

ResMed Targets 12%-14% EPS Growth as GLP-1 Patients Lift Sleep Therapy Demand

ResMed (NYSE:RMD) outlined its growth outlook, margin strategy and portfolio plans during a Morgan Stanley discussion, with executives emphasizing demand generation, patient adherence and ongoing...

Never miss news about ResMed

Track ResMed and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.